-
公开(公告)号：US20090093462A1
公开(公告)日：2009-04-09
申请号：US11665651
申请日：2005-10-19
申请人： Ulricn Abel , Holger Deppe , Achim Feurer , Ulrich Gradler , Kerstin Otte , Renate Sekul , Meinolf Thiemann , Andreas Goutopoulos , Matthias Schwarz , Xuliang Jiang
发明人： Ulricn Abel , Holger Deppe , Achim Feurer , Ulrich Gradler , Kerstin Otte , Renate Sekul , Meinolf Thiemann , Andreas Goutopoulos , Matthias Schwarz , Xuliang Jiang
IPC分类号： A61K31/44 , C07D405/12 , C07D213/72 , C07D413/12 , C07D401/12 , A61P29/00 , A61K31/4545 , A61K31/55 , A61K31/506 , A61K31/4439 , A61K31/5377 , A61P25/00 , A61P17/00 , C07D413/04 , A61K31/443
CPC分类号： C07D405/12 , C07D213/79 , C07D213/81 , C07D213/89 , C07D295/125 , C07D295/13 , C07D295/32 , C07D401/12
摘要： The invention provides novel, substituted 3-arylamino pyridine compounds (I) pharmaceutically acceptable salts, solvates and prodrug compounds thereof, wherein W, R1, R2, R9, R10, R11, R12, R13, R14 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer, restenosis and inflammation. Also disclosed is the use of such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and pharmaceutical compositions containing such compounds.
摘要翻译： 本发明提供新的取代的3-芳基氨基吡啶化合物（I）其药学上可接受的盐，溶剂合物和前药化合物，其中W，R 1，R 2，R 9，R 10，R 11，R 12，R 13，R 14如说明书中所定义。 这些化合物是MEK抑制剂，可用于治疗过度增殖性疾病，如癌症，再狭窄和炎症。 还公开了这样的化合物在哺乳动物，特别是人类中过度增殖性疾病的治疗和含有这些化合物的药物组合物中的应用。
-
公开(公告)号：US07956191B2
公开(公告)日：2011-06-07
申请号：US11665651
申请日：2005-10-19
申请人： Ulrich Abel , Holger Deppe , Achim Feurer , Ulrich Grädler , Kerstin Otte , Renate Sekul , Meinolf Thiemann , Andreas Goutopoulos , Matthias Schwarz , Xuliang Jiang
发明人： Ulrich Abel , Holger Deppe , Achim Feurer , Ulrich Grädler , Kerstin Otte , Renate Sekul , Meinolf Thiemann , Andreas Goutopoulos , Matthias Schwarz , Xuliang Jiang
IPC分类号： C07D213/72 , C07D213/46
CPC分类号： C07D405/12 , C07D213/79 , C07D213/81 , C07D213/89 , C07D295/125 , C07D295/13 , C07D295/32 , C07D401/12
摘要： The invention provides novel, substituted 3-arylamino pyridine compounds (I) pharmaceutically acceptable salts, solvates and prodrug compounds thereof, wherein W, R1, R2, R9, R10, R11, R12, R13, R14 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer, restenosis and inflammation. Also disclosed is the use of such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and pharmaceutical compositions containing such compounds.
摘要翻译： 本发明提供新的取代的3-芳基氨基吡啶化合物（I）其药学上可接受的盐，溶剂合物和前药化合物，其中W，R 1，R 2，R 9，R 10，R 11，R 12，R 13，R 14如说明书中所定义。 这些化合物是MEK抑制剂，可用于治疗过度增殖性疾病，如癌症，再狭窄和炎症。 还公开了这样的化合物在哺乳动物，特别是人类中过度增殖性疾病的治疗和含有这些化合物的药物组合物中的应用。
-
公开(公告)号：US08524911B2
公开(公告)日：2013-09-03
申请号：US13472721
申请日：2012-05-16
申请人： Ulrich Abel , Holger Deppe , Achim Feurer , Ulrich Grädler , Kerstin Otte , Renate Sekul , Meinolf Thiemann , Andreas Goutopoulos , Matthias Schwarz , Xuliang Jiang
发明人： Ulrich Abel , Holger Deppe , Achim Feurer , Ulrich Grädler , Kerstin Otte , Renate Sekul , Meinolf Thiemann , Andreas Goutopoulos , Matthias Schwarz , Xuliang Jiang
IPC分类号： C07D213/72 , C07D213/46
CPC分类号： C07D405/12 , C07D213/79 , C07D213/81 , C07D213/89 , C07D295/125 , C07D295/13 , C07D295/32 , C07D401/12
摘要： The invention provides novel, substituted 3-arylamino pyridine compounds pharmaceutically acceptable salts, solvates and prodrug compounds thereof, wherein W, R1, R2, R9, R10, R11, R12, R13, R14 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer, restenosis and inflammation. Also disclosed is the use of such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and pharmaceutical compositions containing such compounds.
摘要翻译： 本发明提供新的取代的3-芳基氨基吡啶化合物其药学上可接受的盐，溶剂合物和前药化合物，其中W，R 1，R 2，R 9，R 10，R 11，R 12，R 13，R 14如说明书中所定义。 这些化合物是MEK抑制剂，可用于治疗过度增殖性疾病，如癌症，再狭窄和炎症。 还公开了这样的化合物在哺乳动物，特别是人类中过度增殖性疾病的治疗和含有这些化合物的药物组合物中的应用。
-
公开(公告)号：US20110224192A1
公开(公告)日：2011-09-15
申请号：US13112490
申请日：2011-05-20
申请人： Ulrich Abel , Holger Deppe , Achim Feurer , Ulrich Grädler , Kerstin Otte , Renate Sekul , Meinolf Thiemann , Andreas Goutopoulos , Matthias Schwarz , Xuliang Jiang
发明人： Ulrich Abel , Holger Deppe , Achim Feurer , Ulrich Grädler , Kerstin Otte , Renate Sekul , Meinolf Thiemann , Andreas Goutopoulos , Matthias Schwarz , Xuliang Jiang
IPC分类号： A61K31/55 , A61K31/44 , A61K31/443 , A61K31/5377 , A61K31/4545 , A61K31/4439 , A61K31/444 , A61K31/506 , A61K31/4709 , A61K31/496 , A61K31/4433 , A61P35/00 , A61P29/00 , A61P1/18 , A61P13/12 , A61P17/00 , A61P17/06 , A61P3/10 , A61P27/02 , A61P9/10
CPC分类号： C07D405/12 , C07D213/79 , C07D213/81 , C07D213/89 , C07D295/125 , C07D295/13 , C07D295/32 , C07D401/12
摘要： The invention provides novel, substituted 3-arylamino pyridine compounds pharmaceutically acceptable salts, solvates and prodrug compounds thereof, wherein W, R1, R2, R9, R10, R11, R12, R13, R14 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer, restenosis and inflammation. Also disclosed is the use of such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and pharmaceutical compositions containing such compounds.
摘要翻译： 本发明提供新的取代的3-芳基氨基吡啶化合物其药学上可接受的盐，溶剂合物和前药化合物，其中W，R 1，R 2，R 9，R 10，R 11，R 12，R 13，R 14如说明书中所定义。 这些化合物是MEK抑制剂，可用于治疗过度增殖性疾病，如癌症，再狭窄和炎症。 还公开了这样的化合物在哺乳动物，特别是人类中过度增殖性疾病的治疗和含有这些化合物的药物组合物中的应用。
-
公开(公告)号：US20120295889A1
公开(公告)日：2012-11-22
申请号：US13472721
申请日：2012-05-16
申请人： Ulrich Abel , Holger Deppe , Achim Feurer , Ulrich Grädler , Kerstin Otte , Renate Sekul , Meinolf Thiemann , Andreas Goutopoulos , Matthias Schwarz , Xuliang Jiang
发明人： Ulrich Abel , Holger Deppe , Achim Feurer , Ulrich Grädler , Kerstin Otte , Renate Sekul , Meinolf Thiemann , Andreas Goutopoulos , Matthias Schwarz , Xuliang Jiang
IPC分类号： C07D213/81 , A61K31/5377 , A61K31/496 , A61K31/506 , A61K31/4709 , A61K31/4545 , A61K31/444 , A61K31/443 , A61K31/4439 , A61K31/44 , C07D413/12 , C07D401/12 , C07D413/04 , C07D405/12 , C07D213/79 , A61P9/10 , A61K31/4433 , C07D413/06 , C07D213/89 , C07D401/06 , A61P35/00 , A61P29/00 , A61P1/18 , A61P13/12 , A61P17/00 , A61P9/00 , A61P13/08 , A61P17/06 , A61P3/10 , A61P27/02 , A61P1/00 , A61K31/55
CPC分类号： C07D405/12 , C07D213/79 , C07D213/81 , C07D213/89 , C07D295/125 , C07D295/13 , C07D295/32 , C07D401/12
摘要： The invention provides novel, substituted 3-arylamino pyridine compounds pharmaceutically acceptable salts, solvates and prodrug compounds thereof, wherein W, R1, R2, R9, R10, R11, R12, R13, R14 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer, restenosis and inflammation. Also disclosed is the use of such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and pharmaceutical compositions containing such compounds.
摘要翻译： 本发明提供新的取代的3-芳基氨基吡啶化合物其药学上可接受的盐，溶剂合物和前药化合物，其中W，R 1，R 2，R 9，R 10，R 11，R 12，R 13，R 14如说明书中所定义。 这些化合物是MEK抑制剂，可用于治疗过度增殖性疾病，如癌症，再狭窄和炎症。 还公开了这样的化合物在哺乳动物，特别是人类中过度增殖性疾病的治疗和含有这些化合物的药物组合物中的应用。
-
公开(公告)号：US08198457B2
公开(公告)日：2012-06-12
申请号：US13112490
申请日：2011-05-20
申请人： Ulrich Abel , Holger Deppe , Achim Feurer , Ulrich Grädler , Kerstin Otte , Renate Sekul , Meinolf Thiemann , Andreas Goutopoulos , Matthias Schwarz , Xuliang Jiang
发明人： Ulrich Abel , Holger Deppe , Achim Feurer , Ulrich Grädler , Kerstin Otte , Renate Sekul , Meinolf Thiemann , Andreas Goutopoulos , Matthias Schwarz , Xuliang Jiang
IPC分类号： C07D213/72 , C07D211/70 , A01N43/58
CPC分类号： C07D405/12 , C07D213/79 , C07D213/81 , C07D213/89 , C07D295/125 , C07D295/13 , C07D295/32 , C07D401/12
摘要： The invention provides novel, substituted 3-arylamino pyridine compounds pharmaceutically acceptable salts, solvates and prodrug compounds thereof, wherein W, R1, R2, R9, R10, R11, R12, R13, R14 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer, restenosis and inflammation. Also disclosed is the use of such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and pharmaceutical compositions containing such compounds.
摘要翻译： 本发明提供新的取代的3-芳基氨基吡啶化合物其药学上可接受的盐，溶剂合物和前药化合物，其中W，R 1，R 2，R 9，R 10，R 11，R 12，R 13，R 14如说明书中所定义。 这些化合物是MEK抑制剂，可用于治疗过度增殖性疾病，如癌症，再狭窄和炎症。 还公开了这样的化合物在哺乳动物，特别是人类中过度增殖性疾病的治疗和含有这些化合物的药物组合物中的应用。
-
公开(公告)号：US20070010562A1
公开(公告)日：2007-01-11
申请号：US10486748
申请日：2002-08-13
申请人： Ulrike Bauer , Zach Cheruvallath , Ulrich Deuschle , Elena Dneprovskaia , Tim Gahman , Kristina Giegrich , Ronnie Hanecak , Normand Hebert , John Kiely , Ingo Kober , Manfred Kogl , Harald Kranz , Claus Kremoser , Matthew Lee , Kerstin Otte , Carlton Sage , Manish Sud
发明人： Ulrike Bauer , Zach Cheruvallath , Ulrich Deuschle , Elena Dneprovskaia , Tim Gahman , Kristina Giegrich , Ronnie Hanecak , Normand Hebert , John Kiely , Ingo Kober , Manfred Kogl , Harald Kranz , Claus Kremoser , Matthew Lee , Kerstin Otte , Carlton Sage , Manish Sud
IPC分类号： A61K31/4436 , A61K31/44 , C07D409/04 , C07D213/72
CPC分类号： C07D213/74 , C07B2200/11 , C07D261/08 , C07D277/42
摘要： The present invention relates to compounds according to the general formula (1) which bind to the NR1H4 receptor and act as agonists, antagonists or mixed agonists/antagonists of the NR1H4 receptor. The invention further relates to the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and the production of medicaments using said compounds.
摘要翻译： 本发明涉及结合NR1H4受体并且作为NR1H4受体的激动剂，拮抗剂或混合激动剂/拮抗剂的根据通式（1）的化合物。 本发明还涉及通过所述化合物结合所述核受体和使用所述化合物生产药物来治疗疾病和/或病症。
-
公开(公告)号：US07098336B2
公开(公告)日：2006-08-29
申请号：US10217141
申请日：2002-08-13
申请人： Ulrike Bauer , Zach Cheruvallath , Ulrich Deuschle , Elena Dneprovskaia , Tim Gahman , Kristina Giegrich , Ronnie Hanecak , Normand Hébert , John Kiely , Ingo Kober , Manfred Kögl , Harald Kranz , Claus Kremoser , Matthew Lee , Kerstin Otte , Carlton Sage , Manish Sud
发明人： Ulrike Bauer , Zach Cheruvallath , Ulrich Deuschle , Elena Dneprovskaia , Tim Gahman , Kristina Giegrich , Ronnie Hanecak , Normand Hébert , John Kiely , Ingo Kober , Manfred Kögl , Harald Kranz , Claus Kremoser , Matthew Lee , Kerstin Otte , Carlton Sage , Manish Sud
IPC分类号： C07D239/42 , A61K31/505 , A61K31/506 , A61P35/00
CPC分类号： C07D261/08 , C07B2200/11 , C07D213/74 , C07D239/42 , C07D409/04
摘要： The invention provides compounds according to the general formula (1) which bind to the NR1H4 receptor and act as agonists, antagonists or mixed agonists/antagonists of the NR1H4 receptor. The invention further provides methods of treating diseases and/or conditions through binding of the nuclear receptor by the compounds and the production of medicaments using the compounds.
摘要翻译： 本发明提供了结合NR 1 H 4受体并且作为NR 1 H 4受体的激动剂，拮抗剂或混合激动剂/拮抗剂的根据通式（1）的化合物。 本发明还提供了通过化合物与核受体结合并使用该化合物生产药物来治疗疾病和/或病症的方法。
-
公开(公告)号：US07034046B2
公开(公告)日：2006-04-25
申请号：US10185721
申请日：2002-07-01
申请人： Ulrike Bauer , Zach Cheruvallath , Ulrich Deuschle , Elena Dneprovskaia , Tim Gahman , Kristina Giegrich , Ronnie Hanecak , Normand Hébert , John Kiely , Ingo Kober , Manfred Kögl , Harald Kranz , Claus Kremoser , Matthew Lee , Kerstin Otte , Carlton Sage , Manish Sud
发明人： Ulrike Bauer , Zach Cheruvallath , Ulrich Deuschle , Elena Dneprovskaia , Tim Gahman , Kristina Giegrich , Ronnie Hanecak , Normand Hébert , John Kiely , Ingo Kober , Manfred Kögl , Harald Kranz , Claus Kremoser , Matthew Lee , Kerstin Otte , Carlton Sage , Manish Sud
IPC分类号： A61K31/42 , C07D261/08
CPC分类号： C07D261/08 , C07B2200/11 , C07D213/74 , C07D239/42 , C07D409/04
摘要： The present invention relates to compounds according to the general formula (I) which bind to the nuclear receptor, NR1H4, and act as agonists and antagonists of the NR1H4 receptor. The invention further relates to the treatment of diseases and/or conditions through binding of the nuclear receptor by the compounds.
-
公开(公告)号：US06974830B2
公开(公告)日：2005-12-13
申请号：US10185731
申请日：2002-07-01
申请人： Ulrike Bauer , Zach Cheruvallath , Ulrich Deuschle , Elena Dneprovskaia , Tim Gahman , Kristina Giegrich , Ronnie Hanecak , Normand Hébert , John Kiely , Ingo Kober , Manfred Kögl , Harald Kranz , Claus Kremoser , Matthew Lee , Kerstin Otte , Carlton Sage , Manish Sud
发明人： Ulrike Bauer , Zach Cheruvallath , Ulrich Deuschle , Elena Dneprovskaia , Tim Gahman , Kristina Giegrich , Ronnie Hanecak , Normand Hébert , John Kiely , Ingo Kober , Manfred Kögl , Harald Kranz , Claus Kremoser , Matthew Lee , Kerstin Otte , Carlton Sage , Manish Sud
IPC分类号： A61K31/42 , A61K31/506 , A61P3/04 , A61P9/00 , A61P35/00 , C07D213/74 , C07D239/42 , C07D261/08 , C07D277/38 , A61K31/426 , C07D277/20
CPC分类号： C07D261/08 , C07B2200/11 , C07D213/74 , C07D239/42 , C07D409/04
摘要： The present invention relates to compounds according to the general formula (I) which bind to the NR1H4 receptor and act as agonists of the NR1H4 receptor. The invention further relates to the treatment of diseases and/or conditions through binding of the nuclear receptor by the compounds and the production of medicaments using the compounds.
摘要翻译： 本发明涉及结合NR1H4受体并作为NR1H4受体激动剂的通式（I）的化合物。 本发明还涉及通过化合物与核受体的结合和使用该化合物的药物的生产来治疗疾病和/或病症。
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.034 秒)
